A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis. Subjects who meet the study entry criteria will be randomized in a 1:1:1 ratio to receive twice daily topical doses of B244 O.D. 5.0, B244 O.D. 20.0, or vehicle (placebo) for 4 weeks.

开始日期2020-06-24

申办/合作机构

AOBiome LLC

[+1]

NCT03775434

/ Completed临床1期

An Open-label, Multicenter, Phase Ib Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects Aged 2 to 17 Years With Atopic Dermatitis

An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis
Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b

开始日期2018-12-07

申办/合作机构

AOBiome LLC

[+1]

NCT03590366

/ Completed临床2期

A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea

This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.

开始日期2018-07-02

申办/合作机构

AOBiome LLC

[+1]

100 项与 B-244 相关的临床结果

登录后查看更多信息

100 项与 B-244 相关的转化医学

登录后查看更多信息

100 项与 B-244 相关的专利（医药）

登录后查看更多信息

项与 B-244 相关的文献（医药）

2024-10-12·Journal of Biomolecular Structure and Dynamics

Identification of potential inhibitors of Mtb InhA: a pharmacoinformatics approach

Article

作者: Kamera, Sreelatha ; Sharma, Vishnu Kumar ; Prasad V., Bharatam ; Garlapati, Achaiah

The emergence of superbugs of multi-drug resistant (MDR/RR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (Mtb) strains at a faster rate is posing a serious threat to Tuberculosis (TB) control worldwide. Mtb enoyl-acyl carrier protein reductase (InhA) is a well-established target of the front-line anti-TB prodrug Isoniazid (INH), which requires activation by Catalase-peroxidase enzyme (KatG) in order to inhibit InhA enzyme, that is crucial for the biosynthesis of the mycobacterial cell wall. Currently, due to widespread resistance to this drug, it is necessary to identify new clinical candidates that directly inhibit InhA enzyme and do not require activation by KatG, thereby circumventing most of the resistance mechanisms. In the present study, high-throughput virtual screening of ASINEX database was carried out to identify potential direct inhibitors of Mtb InhA. Best twenty compounds with good binding energies ranging between -12.36 and -9.27 kcal/mol were selected as promising virtual screening hits. These molecules were subjected to ADME study followed by toxicity prediction. Finally, four top-ranked molecules which are structurally diverse and possess best binding affinity than the co-crystalized ligand have been chosen for MD simulation studies followed by MM-GBSA analysis to validate and ensure the stability of hits in the active site of the enzyme. Based on the 100 ns MD simulation studies and binding free energy estimates, three hit molecules B244, B369, and B310 could be considered as potential inhibitors for Mtb InhA, which are likely to be potent against INH-resistant Mtb strains after successful experimental validation.Communicated by Ramaswamy H. Sarma.

2024-07-02·Expert Opinion on Emerging Drugs

Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials

Review

作者: Su, Malcolm ; Obed, Ogechi ; Chong, Albert C. ; Ong, Peck Y.

INTRODUCTIONAtopic dermatitis (AD) is an inflammatory skin condition that affects millions of pediatric and adult patients with well-studied impact on morbidity and quality of life. Management occurs in a stepwise fashion beginning with preventative measures before immunomodulators are introduced. However, challenges remain in treatment of moderate-to-severe atopic dermatitis that is refractory to first- and second-line treatments and there are only few topical anti-inflammatory options, especially for pediatric patients.AREAS COVEREDNew medications are required to address these gaps as lesions may persist despite treatment or patients may discontinue treatment due to actual or anticipated adverse effects of mainstay medications. Emerging research into the pathophysiology of AD and the immune system at large has provided opportunities for novel interventions aimed at stopping AD mechanisms at new checkpoints. Clinical trials for 36 agents currently in phase 2 or phase 3 are evaluated with particular focus on the studies for, B244, CBP-201, tapinarof, lebrikizumab, nemolizumab, amlitelimab, and rocatinlimab as they explore novel pathways and have some of the most promising results.EXPERT OPINIONThese clinical trials contribute to the evolution of AD treatment toward greater precision based on salient pathways with a particular focus on moderate-to-severe AD to enhance efficacy and minimize adverse effects.

2023-06-01·EClinicalMedicine

Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial.

Article

作者: Kim, Hyun D ; Simpson, Eric L ; Lio, Peter A ; Ng-Cashin, Judith ; Gryllos, Ioannis ; Bliss, Robin L ; Krueger, Todd ; Brownell, Daniel R ; Li, Connie ; Silverberg, Jonathan I ; Swaidan, Victoria R

BackgroundTopical anti-inflammatory therapy is a cornerstone of treatment for atopic dermatitis (AD). However, many unmet needs remain with existing therapies. B244 is a live topical biotherapeutic being tested for the reduction of pruritus and improvement of eczema signs in patients with AD. We aimed to assess the safety and efficacy of B244, compared to vehicle, for patients with mild-to-moderate AD and moderate-to-severe pruritus.MethodsIn this randomised, placebo-controlled, double-blind phase 2b trial, adults aged 18-65 years with mild-to-moderate AD and moderate-to-severe pruritus were enrolled across 56 sites in the USA. Patients were randomised 1:1:1 into a low-dose (optical density at 600 nm [OD] 5.0), high-dose (OD 20.0), or vehicle group for the 4-week treatment period and a 4 week follow-up period. Patients were instructed to apply the topical spray twice daily throughout the treatment period. Randomisation was centrally based (random alternating blocks of 6 and 3) and stratified by site. All participants, investigators, and those assessing outcomes were blinded to the treatment group assignments. The primary endpoint was the mean change in pruritus as measured by the Worst Itch Numeric Rating Scale (WI-NRS) at 4 weeks. Safety was tracked throughout the study. Primary efficacy analyses included the modified intent-to-treat (mITT) population, encompassing those who received at least one dose of study drug and attended at least one post-baseline visit. The safety population included all participants who received at least one does of study drug. This study is registered with ClinicalTrials.gov, NCT04490109.FindingsBetween June 4, 2020 and October 22, 2021, 547 eligible patients were enrolled. All study endpoints were meaningfully improved with B244 compared to vehicle. The WI-NRS score was reduced by 34% (-2.8 B244 vs -2.1 placebo, p = 0.014 and p = 0.015 for OD 20.0 and OD 5.0), from a baseline score of >8. B244 was well tolerated with no serious adverse events (SAEs); treatment-emergent adverse events (TEAEs) and treatment related TEAEs were low in incidence, mild in severity, and transient. 33 (18%) of 180 patients given B244 OD 5.0, 29 (16%) of 180 patients given B244 OD 20.0, and 17 (9%) of 186 patients given placebo reported treatment-emergent adverse events; headache was the most frequent (3%, 2%, and 1%, respectively).InterpretationB244 was well tolerated and demonstrated improved efficacy compared to vehicle in all primary, secondary, and exploratory endpoints and should be further developed as a novel, natural, fast-acting topical spray treatment option for AD and associated pruritus.FundingAOBiome Therapeutics.

项与 B-244 相关的新闻（医药）

2024-01-10

·maruho.co.jp

AOBiome and Maruho have entered into an Exclusive License Agreement for a Novel Therapeutic for the treatment of Atopic Dermatitis in Japan

Osaka (Japan), January 10, 2024 - Maruho Co., Ltd. ("Maruho"; Head Office: Osaka; President and CEO, Atsushi Sugita) announces that it has entered into an exclusive license agreement (the "Agreement") with AOBiome, LLC ("AOBiome", Head Office: Cambridge, Massachusetts (USA); President and CEO, Todd Krueger) for B244 (development code) for the treatment of atopic dermatitis. Under the license agreement, AOBiome grants Maruho an exclusive license to develop, manufacture, and commercialize B244 in Japan, and Maruho will pay AOBiome an upfront payment. Maruho may also make additional milestone payments depending on achievement of development and commercialization milestones. Maruho also has the rights to B244 for additional diseases other than atopic dermatitis. Maruho plans to advance the development of B244 in Japan by participating in the global Phase 3 clinical studies that AOBiome is planning in Japan, the U.S. and Europe for the treatment of adult patients with atopic dermatitis. B244 is a topical biologic formulation being developed by AOBiome, leveraging ammonia-oxidizing bacterium. B244 reduces the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-311). In a late stage Phase 2 clinical study conducted in the U.S. by AOBiome in adult patients with atopic dermatitis, B244 was found to be safe and effective for the treatment of appearance and itching related to atopic dermatis2). Maruho is committed to contributing to the smiles of patients by providing a new treatment option for atopic dermatitis. NoteThe information contained in this news release in regard to pharmaceutical and developmental products is not intended for the purpose of promotion, advertising or medical advice. About AOBiomeAOBiome, LLC. is a Cambridge, MA-based life sciences company. AOBiome is engaged in the development of topical therapeutics for inflammatory conditions using its live biotherapeutic B244. For more information, please visit https://www.aobiome.com/ About Ammonia Oxidizing BacteriaAmmonia Oxidizing Bacteria is a general term for bacteria that oxidize ammonia to nitric oxide and nitrite. The genus Nitrosomonas is a representative example. About MaruhoMaruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,566 employees (as of the end of September 2023), and net sales were approximately 85.71 billion yen in its fiscal year ended September 30, 2023. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile. For more information, please visit www.maruho.co.jp/english/ References1）https://www.aobiome.com/aob-inflammatory-conditions-and-systemic-effects/ 2）https://www.aobiome.com/press/press-releases/?y=2023 Contact Information: Maruho Co., Ltd. Public Relations Group, Corporate Planning Dept. Tel：+81-(0)6-6371-8831 Fax：+81-(0)6-6371-8679 e-mail：kouhou@mii.maruho.co.jp

临床2期引进/卖出临床3期临床结果临床1期

2024-01-09

·今日头条

AOBiome达成新合作，推动活菌药日本3期试验

本期看点 ① AOBiome与Maruho达成独家授权与合作协议 ② Resalis Therapeutics获得千万欧元A轮融资 ③ 布鲁克收购拉曼光谱公司Tornado Spectral Systems ④ 瑞利光电获投数百万元，加速FRET显微成像系统商业化落地 ⑤ Accord BioPharma宣布FDA接受喜达诺仿制药DMB-3115的BLA ⑥ 德人乳业：乳品、果蔬饮料生产线即将投产 ① AOBiome与Maruho达成独家授权与合作协议作者：AOBiome Therapeutics 解读：Richard 来源：AOBiome Therapeutics官网发布日期：2024-01-05 ■ 内容要点 1月5日，生物科技公司AOBiome Therapeutics宣布与日本Maruho公司就其皮肤外用生物制剂B244，达成了一项独家授权和合作开发协议。根据双方协议， Maruho公司将负责B244在日本的商业化事宜和日本境内的3期临床开展，并向AOBiome Therapeutics公司支付预付款、里程碑付款和销售提成在内的费用。与此同时，Maruho公司将拥有B244所有适应证产品权益。 B244的有效成分为一种氨氧化菌，可以将皮肤表面的铵盐转化为亚硝酸盐和一氧化氮，发挥抗菌、抗炎和舒张血管的作用，其适应证包括特异性皮炎和皮肤瘙痒等。目前，AOBiome Therapeutics公司正着手开展B244治疗特异性皮炎相关3期临床研究。原文链接： https://www.aobiome.com/press/press-releases/ ② Resalis Therapeutics获得千万欧元A轮融资作者：Resalis Therapeutics 解读：Johnson 来源：Biospace 发布日期：2024-01-04 ■ 内容要点 1月4日，专注于RNA药物研发的生物科技公司Resalis Therapeutics宣布，获得了1000万欧元（约合人民币7819万元）的A轮融资。风投机构Sunstone Life Science Ventures领衔了本次投资，参与投资的还有Claris Ventures公司和天使投资人等。融资将用于推进Resalis Therapeutics公司肥胖症管线药物RES-010的1期临床试验，从而为2期临床试验做好准备。管线药物RES-010是一种靶向miR-22的非编码RNA化合物，miR-22是调节脂质代谢和能量消耗的核心靶标。该药物旨在为肥胖患者提供长效减肥效果，或者与GLP-1受体激动剂类药物联用延长其药效。目前，该管线药物已在美国、日本和中国获得专利授权，欧洲专利正处于申请阶段。原文链接： https://www.biospace.com/article/releases/resalis-therapeutics-raises-10-million-series-a-to-complete-first-clinical-trial-for-res-010-in-obesity/ ③ 布鲁克收购拉曼光谱公司Tornado Spectral Systems 作者：解读：拍了花宝贝来源：Biospace 发布日期：2024-01-04 ■ 内容要点 1月4日，分析仪器公司布鲁克（Bruker）宣布，收购加拿大拉曼光谱企业Tornado Spectral Systems，此举旨在丰富布鲁克公司在生物制药领域过程分析技术（PAT）上的产品组合。拉曼光谱作为一种无损检测技术，可应用于检测微生物代谢物，研究微生物与机体、细胞与细胞、细胞与环境之间的分子交换，以及研究不同环境下微生物的多样性等科学问题。Tornado Spectral Systems是一家专门设计、制造和销售拉曼光谱分析仪的公司，并拥有十多年的行业经验。其开发的专利高通量虚拟狭缝（HTVS）技术即使在高难度的拉曼分析中也能获得高质量的光谱。与传统拉曼光谱仪相比，Tornado Spectral Systems公司开发的拉曼分析仪具备出色的性能，可在混合物和低浓度下进行更准确的化学识别和定量。原文链接： https://www.biospace.com/article/releases/bruker-announces-acquisition-of-tornado-spectral-systems-to-expand-its-biopharma-process-analytical-technology-pat-product-portfolio/ ④ 瑞利光电获投数百万元，加速FRET显微成像系统商业化落地作者：解读：Johnson 来源：动脉网发布日期：2024-01-06 ■ 内容要点 1月6日，瑞利光电科技（珠海）有限公司（以下简称“瑞利光电”）宣布，获得广州力华投资有限公司数百万元投资。瑞利光电成立于2023年，由华南师范大学庄正飞、陈同生教授联合创立，是一家致力于高端荧光共振能量转移（FRET）显微成像系统的研发、生产和销售、提供科研检测服务的高新技术企业，荣登广东省工业和信息化厅公布的“2023年专精特新中小企业名单”。公司的FRET技术具有唯一可以在活细胞内可视化分子结构与功能的能力。团队深耕FRET技术24年，开发了一系列具有自主知识产权的FRET硬件和算法，形成了系列活细胞定量FRET显微成像分析仪、配套显微镜光源等产品；取得与业务密切相关的自主知识产权30余项，参与制定IEC国际标准2项。此外，公司还储备了SIM-FRET超分辨FRET显微分析系统、FRET药物筛选系统、多波长LED光源、高端显微镜机架等可产业化的技术成果。原文链接： https://www.vbdata.cn/1518945985 ⑤ Accord BioPharma宣布FDA接受喜达诺仿制药DMB-3115的BLA 作者：Biospace 解读：617 来源：Biospace 发布日期：2024-01-04 ■ 内容要点 1月4日，Intas Pharmaceuticals旗下子公司Accord BioPharma宣布，美国食品药品监督管理局（FDA）已接受STELARA仿制药DMB-3115的生物制剂许可申请（BLA）。 STELARA（中文商品名：喜达诺，通用名：ustekinumab，乌司奴单抗注射液）是杨森生物技术公司开发的一款药物，已被批准用于治疗克罗恩病、溃疡性结肠炎、斑块状银屑病、银屑病关节炎等疾病。2022年，STELARA在美国的销售额高达139亿美元，是最畅销的生物制剂之一。 DMB-3115的开发工作始于2013年，由Dong-A Socio Holdings和Meiji Seika Pharma公司联合完成。2021年，Intas Pharmaceuticals公司获得了DMB-3115的独家商业化权利，并由其旗下子公司Accord BioPharma负责美国的商业化工作。此次BLA的申请是基于针对斑块状银屑病患者的3期多区域临床试验的结果，试验的主要终点为银屑病面积和皮肤症状严重指数（PASI）的变化率。临床结果表明，DMB-3115与其参考产品STELARA高度相似，在质量、安全性和疗效方面不存在有临床意义的差异。原文链接： https://www.biospace.com/article/releases/accord-biopharma-inc-announces-u-s-fda-acceptance-of-biologics-license-application-for-proposed-stelara-biosimilar-dmb-3115/ ⑥ 德人乳业：乳品、果蔬饮料生产线即将投产作者：解读：617 来源：FoodTalks 发布日期：2024-01-08 ■ 内容要点近日，娄底德人乳业有限公司乳品、果蔬饮料加工厂项目进入生产线设备安装调试阶段，预计1月20日前投产使用。娄底德人乳业有限公司乳品、果蔬饮料加工厂项目于2022年3月开始建设，总投资4700万元，工厂地址位于湖南省娄底市新化县高新技术产业开发区梅苑工业园，工厂总用地面积16650平方米。建设内容包括厂房、仓库、辅助车间、研学车间以及绿化工程和土石方工程等配套工程。据悉，娄底德人乳业有限公司是一家以液态奶为核心，集牧草种植、奶牛养殖、乳品加工、乳品销售、牧场观光和创新创业六位为一体的全产业链企业。公司为湖南德人牧业集团旗下子公司，是德人牧业集团按照“一城一场一厂”规划，在湘中地区布局的前沿阵地，将致力于为消费者提供安全、新鲜、健康、营养的乳制品。原文链接： https://www.foodtalks.cn/flash/18831

临床3期并购临床2期引进/卖出临床结果

2024-01-05

·PRNewswire

AOB Pharma and Maruho enter into an Exclusive License Agreement for AOB Pharma's Topical Biologic B244 for the Treatment of Inflammatory Indications including Atopic Dermatitis in Japan

The license is exclusive for the territory of Japan and contains rights for future indications Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis encompassing Japan, the US, and EU The deal includes upfront payments, milestone payments and ongoing royalties. CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- AOBiome Therapeutics Inc. ("AOB"), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB's topical biologic B244 (currently preparing for global Phase 3 clinical trials), a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch). The license is for all indications treated by the B244 platform. Under the license agreement, Maruho will commercialize the product exclusively in Japan. Based on the license agreement, AOB will supply the product to Maruho, and Maruho will make an upfront payment and may also make additional milestone payments depending on achievement of development and commercialization milestones. Maruho also has the rights to AOB's B244 for all additional indications including later stage programs related to inflammation. "B244 offers an opportunity to extend our portfolio for the treatment of Atopic Dermatitis as well as other inflammatory indications. It's unique safety profile and efficacy will allow us to continue our leadership in treating Atopic Dermatitis while improving patients' lives. We look forward to continuing to develop the treatment in collaboration with AOB Pharma." says Atsushi Sugita, President and CEO of Maruho. "We are excited to be partnering with Maruho as they are the leading dermatology player in Japan. We view this as validation of B244's potential to address unmet market needs, not just in Japan but globally. We could not have found a better collaborator as we develop our programs for Japanese patients. This model will serve as an example as we fill out our worldwide strategy." says AOBiome's President & CEO, Todd Krueger. AOB is in the process of planning global Phase 3 studies for B244 in Atopic Dermatitis, for which it aims to start recruiting patients in the second half 2024. The Japanese portion of the Phase 3 trials will be run in Japan by Maruho. About B244 AOB's B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be well-tolerated in clinical studies to date. Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. See full article at: . About AOB Therapeutics, Inc. AOBiome Therapeutics Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical therapeutics for inflammatory conditions. AOB is advancing a pipeline of multiple, clinical-stage therapeutic candidates. Learn more at AOBPharma.com. About Maruho Maruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,547 employees (as of the end of September 2022), and net sales were approximately 85.67 billion yen in its fiscal year ended September 30, 2022. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile. For more information, please visit Contacts: For Media Inquiries: Jim Hoffman 845-417-3487 [email protected] SOURCE AOBiome Therapeutics

引进/卖出临床3期微生物疗法

100 项与 B-244 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	临床3期	-	AOBiome Therapeutics, Inc.	-
偏头痛	药物发现	美国	AOBiome LLC	2018-03-30
轻度特应性皮炎	药物发现	美国	AOBiome LLC	2018-01-15
中度特应性皮炎	药物发现	美国	AOBiome LLC	2018-01-15
过敏性鼻炎	药物发现	加拿大	AOBiome LLC	2017-09-19
过敏性鼻炎	药物发现	美国	AOBiome LLC	2017-09-19
季节性过敏性鼻炎	药物发现	美国	AOBiome LLC	2017-09-19
季节性过敏性鼻炎	药物发现	加拿大	AOBiome LLC	2017-09-19
高血压	药物发现	美国	AOBiome LLC	2016-11-01
高血压前期	药物发现	美国	AOBiome LLC	2016-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03775434 (CTgov)	临床1期	湿疹 \| 特应性皮炎	28	Experimental: B244	構齋範選繭遞夢醖廠蓋(鹹夢願窪顧蓋積鹹願鏇) = 衊糧廠艱顧網繭夢鑰窪繭鹽醖構膚壓遞鑰衊廠 (簾窪鹽構繭蓋醖範遞願, 製鏇遞鬱繭範繭簾構襯 ~ 窪鹽膚鑰範衊製遞積遞) 更多	-	2024-08-05
NCT03235024 (CTgov)	临床2期	中度特应性皮炎 \| 轻度特应性皮炎 \| 特应性皮炎	122	B244 (B244)	憲觸觸淵鑰網遞鬱製廠(廠艱顧壓鑰窪築鹹構餘) = 繭獵繭膚簾遞淵繭鏇選鑰簾範窪鹽鹹鹽廠餘淵 (觸選鏇遞襯艱獵襯築衊, 願繭製範窪鬱艱鏇襯壓 ~ 積鹹積網選廠艱顧艱糧) 更多	-	2022-10-10
				Vehicle (Vehicle)	憲觸觸淵鑰網遞鬱製廠(廠艱顧壓鑰窪築鹹構餘) = 選壓餘鹽選鏇衊醖衊鑰鑰簾範窪鹽鹹鹽廠餘淵 (觸選鏇遞襯艱獵襯築衊, 廠衊糧構顧製蓋築夢構 ~ 遞築憲夢鏇壓遞糧觸廠) 更多
NCT03488563 (CTgov)	临床2期	偏头痛	313	B244 (B244 Dose 1)	糧壓蓋淵艱廠餘蓋餘憲(鬱鏇鏇膚襯鏇簾願廠憲) = 簾製艱繭廠糧鑰餘餘築鑰築衊遞獵衊觸觸淵齋 (顧獵範醖鹹膚觸獵積鏇, 顧網繭膚艱鹽製觸窪網 ~ 鏇顧壓餘蓋艱艱繭範鏇) 更多	-	2022-10-04
				B244 (B244 Dose 2)	糧壓蓋淵艱廠餘蓋餘憲(鬱鏇鏇膚襯鏇簾願廠憲) = 網蓋範夢壓鏇鑰憲襯範鑰築衊遞獵衊觸觸淵齋 (顧獵範醖鹹膚觸獵積鏇, 獵願憲選夢餘繭鬱廠鏇 ~ 鹹衊選顧願餘醖積餘壓) 更多
NCT03775434 (Biospace) 人工标引	临床2期	瘙痒 \| 特应性皮炎	30	B244 (adult subjects)	(壓製範壓蓋獵齋鑰窪構) = No adverse events 壓積網窪夢蓋淵鬱鬱構 (鏇餘遞艱醖糧繭製艱願 )	积极	2022-09-20
				B244 (pediatric subjects)
NCT04490109 (Biospace) 人工标引	临床2期	瘙痒 \| 特应性皮炎	547	B244	(簾廠築鬱獵簾鬱襯憲遞) = 艱築製願遞獵糧窪鑰餘積遞網範糧齋鹹壓窪鹹 (獵網衊簾膚夢簾憲構窪 ) 更多	积极	2022-09-20
NCT03590366 (CTgov)	临床2期	玫瑰痤疮	140	B244 (B244)	觸鏇齋構醖願製觸願夢(鹽網範鹹範獵淵襯範鹽) = 窪襯願憲糧衊鬱壓選製鹹製醖窪襯醖窪鑰鹹壓 (衊網鹽壓襯願簾窪鹹積, 廠範夢壓顧壓憲範簾鹽 ~ 鑰糧製積齋鏇網獵獵選) 更多	-	2022-09-16
				Vehicle (Vehicle)	觸鏇齋構醖願製觸願夢(鹽網範鹹範獵淵襯範鹽) = 獵積蓋淵網壓積鹹鑰鏇鹹製醖窪襯醖窪鑰鹹壓 (衊網鹽壓襯願簾窪鹹積, 獵膚糧廠製鑰糧範夢鹽 ~ 簾築窪簾齋醖憲窪觸鬱) 更多
NCT02832063 (CTgov)	临床2/3期	寻常痤疮	372	B244 (B244 Arm)	鹹餘鹹築構築簾鹹襯艱(憲糧襯願鬱鑰夢壓蓋獵) = 鑰鑰鹽壓膚憲鹽醖鏇範繭觸顧鹽積選範鏇範鹽 (構壓築齋艱遞鑰積鏇鹹, 鏇鏇壓夢鏇窪積築鏇衊 ~ 積簾積醖淵網鏇糧窪窪) 更多	-	2022-09-16
				Placebo (Placebo Arm)	鹹餘鹹築構築簾鹹襯艱(憲糧襯願鬱鑰夢壓蓋獵) = 顧餘積壓夢鏇醖範餘鏇繭觸顧鹽積選範鏇範鹽 (構壓築齋艱遞鑰積鏇鹹, 醖鹽顧繭願遞襯築廠衊 ~ 鹽築鹽鑰範夢構艱網廠) 更多
NCT03290248 (Biospace) 人工标引	临床1期	季节性过敏性鼻炎	24	B-244	(糧鑰蓋鏇窪淵選齋膚網) = There were no serious adverse events 醖鹽壓糧顧憲蓋壓鹹衊 (淵艱選積廠齋顧鏇積憲 ) 更多	积极	2018-03-21
				Placebo